These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17329907)

  • 41. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.
    Cohen RD
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S17-22. PubMed ID: 11380038
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab.
    Mantzaris GJ; Viazis N; Petraki K; Papamichael K; Theodoropoulos I; Roussos A; Karakoidas C; Koilakou S; Raptis N; Smyrnidis A; Agalos G; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1042-8. PubMed ID: 20139856
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mechanisms in failure of infliximab for Crohn's disease.
    Nikolaus S; Raedler A; Kühbacker T; Sfikas N; Fölsch UR; Schreiber S
    Lancet; 2000 Oct; 356(9240):1475-9. PubMed ID: 11081530
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease.
    Harper JW; Sinanan MN; Zisman TL
    Inflamm Bowel Dis; 2013 Sep; 19(10):2118-24. PubMed ID: 23863401
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Endoscopic monitoring of infliximab therapy in Crohn's disease.
    af Björkesten CG; Nieminen U; Turunen U; Arkkila PE; Sipponen T; Färkkilä MA
    Inflamm Bowel Dis; 2011 Apr; 17(4):947-53. PubMed ID: 20860048
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
    Sandborn WJ; Hanauer S; Loftus EV; Tremaine WJ; Kane S; Cohen R; Hanson K; Johnson T; Schmitt D; Jeche R
    Am J Gastroenterol; 2004 Oct; 99(10):1984-9. PubMed ID: 15447761
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Is really megacolon a contraindication to infliximab in Crohn's disease?
    Sinagra E; Orlando A; Renna S; Criscuoli V; La Seta F; Olivo M; Ciofalo M; Cottone M
    Acta Gastroenterol Belg; 2013 Dec; 76(4):442-4. PubMed ID: 24592552
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn's Disease Is Determined by Their Concentration.
    Edlund H; Steenholdt C; Ainsworth MA; Goebgen E; Brynskov J; Thomsen OØ; Huisinga W; Kloft C
    AAPS J; 2017 Jan; 19(1):223-233. PubMed ID: 27739011
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of nutritional status on the therapeutic effect of infliximab in patients with Crohn's disease.
    Sumi R; Nakajima K; Iijima H; Wasa M; Shinzaki S; Nezu R; Inoue Y; Ito T
    Surg Today; 2016 Aug; 46(8):922-9. PubMed ID: 26438200
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [A comparative study of induction of remission and cost-effectiveness of enteral nutrition versus infliximab in moderate-to-severe Crohn's disease].
    Zhu WM; Zuo LG; Li Y; Cao L; Zhang W; Gu YF; Xu M; Li N; Li JS
    Zhonghua Nei Ke Za Zhi; 2013 Sep; 52(9):721-5. PubMed ID: 24314158
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study.
    Biancone L; Orlando A; Kohn A; Colombo E; Sostegni R; Angelucci E; Rizzello F; Castiglione F; Benazzato L; Papi C; Meucci G; Riegler G; Petruzziello C; Mocciaro F; Geremia A; Calabrese E; Cottone M; Pallone F
    Gut; 2006 Feb; 55(2):228-33. PubMed ID: 16120759
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab.
    Medrano LM; Taxonera C; Márquez A; Barreiro-de Acosta M; Gómez-García M; González-Artacho C; Pérez-Calle JL; Bermejo F; Lopez-Sanromán A; Martín Arranz MD; Gisbert JP; Mendoza JL; Martín J; Urcelay E; Núñez C
    Hum Immunol; 2014 Jan; 75(1):71-5. PubMed ID: 24121042
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
    Keating GM; Perry CM
    BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical pharmacokinetics and use of infliximab.
    Klotz U; Teml A; Schwab M
    Clin Pharmacokinet; 2007; 46(8):645-60. PubMed ID: 17655372
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
    Kierkus J; Dadalski M; Szymanska E; Oracz G; Wegner A; Gorczewska M; Szymanska S; Woynarowski M; Ryzko J
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Absence of Relationship Between Crohn's Disease Activity Index or C-Reactive Protein and Infliximab Exposure Calls for Objective Crohn's Disease Activity Measures for the Evaluation of Treatment Effects at Treatment Failure.
    Edlund H; Grisic AM; Steenholdt C; Ainsworth MA; Brynskov J; Huisinga W; Kloft C
    Ther Drug Monit; 2019 Apr; 41(2):235-242. PubMed ID: 30883516
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS).
    Sussman DA; Kubiliun N; Mulani PM; Chao J; Gillis CA; Yang M; Lu M; T Abreu M
    Inflamm Bowel Dis; 2012 Nov; 18(11):2043-55. PubMed ID: 22241679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.